Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09GIA
|
|||
| Former ID |
DNCL003736
|
|||
| Drug Name |
SAR391786
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Muscle atrophy [ICD-11: FB32.Y] | Phase 2 | [1] | |
| Company |
Sanofi
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Growth/differentiation factor 8 (GDF-8) | Target Info | . | [2] |
| Panther Pathway | TGF-beta signaling pathway | |||
| WikiPathways | Hypertrophy Model | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01963598) Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia. U.S. National Institutes of Health. | |||
| REF 2 | Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact. 2010 Mar;10(1):56-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.